Evidence map›Paper›PMID 42038244›Full record

Trial reportFrontiers in pediatrics2026

Lactoferrin combined with

Zhe Shi, Huajiang Zhu, Xiaohan Tao, Feitong Liu, Lingling Zhao, Jiahui Zhang, Jinping Zhang

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhe ShiDepartment of Pediatrics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huajiang ZhuDepartment of Public Health, Shanghai Pudong New Area Shuyuan Community Health Service Center, Shanghai, China.
Xiaohan TaoH&H Group, China Research and Innovation Center, Guangzhou, China.
Feitong LiuH&H Group, China Research and Innovation Center, Guangzhou, China.
Lingling ZhaoH&H Group, China Research and Innovation Center, Guangzhou, China.
Jiahui ZhangDepartment of Pediatrics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jinping ZhangDepartment of Pediatrics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives and study: To explore the effects and mechanisms of lactoferrin combined with Methods: Eligible healthy children aged 0-6 years were randomized into intervention group (IG, Results: After the intervention, the incidence of RTIs showed no significant difference between groups (55% vs. 61.8%, Conclusions: The intervention improved clinical outcomes and induced phylogenetic restructuring of the gut microbiota rather than changes in overall abundance, accompanied by a shift toward greater stability in gut microbial structure and energy metabolic patterns. Clinical Trial Registration: identifier ChiCTR2500111308.

Indexed as

bifidobacteriumgut microbiomehost–microbe interactionsmicrobiome-metabolome interactionsrespiratory tract infections

Identifiers

PMID42038244
PMCPMC13106167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.